세계의 DNA 백신 시장 : 유형, 용도, 최종 사용자, 전달 방법, 기술, 치료 영역, 투여 경로별 예측(2025-2030년)

The DNA Vaccine Market was valued at USD 263.93 million in 2023, expected to reach USD 302.54 million in 2024, and is projected to grow at a CAGR of 13.84%, to USD 654.23 million by 2030.

DNA vaccines represent a significant advancement in immunization technology, involving the direct introduction of genetically engineered DNA to produce an immunological response. These vaccines are crucial in addressing diseases that traditional vaccines may struggle with, offering a more streamlined production process with long-lasting and broad immune responses. Historically niche, their necessity has surged amidst rising global health challenges such as emerging infectious diseases and bioterrorism threats. DNA vaccines exhibit a versatile application scope, from human and veterinary vaccines to cancer and chronic disease treatments, with end-uses extending to personal healthcare and public health initiatives.

Market growth is primarily influenced by advancements in genetic engineering technologies, increasing R&D investments, and a supportive regulatory environment that's gradually adapting to novel therapeutics. An aging global population and heightened awareness of preventive healthcare further bolster market demand. A pivotal opportunity lies in emerging markets, where public health needs catalyze rapid adoption of innovative vaccination strategies. Companies can capitalize here by investing in localized manufacturing and distribution infrastructures.

Challenges remain, such as high initial R&D costs, issues with vaccine stability, and public apprehension concerning genetic technologies. Regulatory hurdles across different jurisdictions also pose significant risks. Meanwhile, innovation can pivot around enhancing vaccine delivery systems, such as electroporation methods, and improving thermal stability for easier distribution. Research initiatives focusing on expanding the immunogenic profile of DNA vaccines could address existing limitations and broaden applicability.

The DNA vaccine market is both nascent and rapidly evolving, demanding keen strategic positioning. Stakeholders should prioritize collaborations with biotech firms and research institutions to fast-track innovation and market entry. Addressing the complex challenge of public and regulatory acceptance will be critical. Ultimately, companies that navigate these dynamics with agility-emphasizing technological flexibility and strategic partnerships-are likely to thrive in the DNA vaccine market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving DNA Vaccine Market

The DNA Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing need for rapid and scalable vaccine production methodologies
  • Enhanced regulatory frameworks supporting the approval and commercialization of DNA vaccines
  • Increasing collaboration between public and private sectors for vaccine development
  • Expansion of vaccination programs in developing regions boosting market growth
• Market Restraints
  • Low awareness and acceptance of DNA vaccine technology among healthcare professionals and patients
  • Technical challenges in ensuring the stability and delivery of DNA vaccines in target cells
• Market Opportunities
  • Rising prevalence of infectious diseases necessitating the development of targeted DNA vaccines
  • Development of personalized DNA vaccines offering tailor-made solutions for individual patient needs
  • Advancements in delivery technologies enhancing the effectiveness and acceptance of DNA vaccines
• Market Challenges
  • Complexities in ensuring cold chain logistics for the distribution of DNA vaccines across different regions
  • Barriers to market entry for new players due to high research and development costs in the DNA vaccine industry

Porter's Five Forces: A Strategic Tool for Navigating the DNA Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the DNA Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the DNA Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the DNA Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the DNA Vaccine Market

A detailed market share analysis in the DNA Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the DNA Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the DNA Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the DNA Vaccine Market

A strategic analysis of the DNA Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the DNA Vaccine Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bioject Medical Technologies Inc., Emergent BioSolutions, ExcellGene SA, Genentech, Inc., GeneOne Life Science, Inc., GeoVax Labs, Inc., Immunomic Therapeutics, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, OncoSec Medical Incorporated, Profectus BioSciences, Inc., TechnoVax Inc., Vaccibody AS, Vaxess Technologies Inc., and Vical Incorporated.

Market Segmentation & Coverage

This research report categorizes the DNA Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Plasmid DNA Vaccine, Recombinant Protein Vaccine, and Viral Vector Vaccine.
• Based on Application, market is studied across Allergy, Infectious Diseases, and Oncology.
• Based on End-User, market is studied across Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical Companies.
• Based on Delivery Method, market is studied across Gene Gun, Jet Injector, and Needle-Free Injection. The Needle-Free Injection is further studied across Biojector and Electroporation.
• Based on Technology, market is studied across Electroporation Delivery, Gene Gun Delivery, and Liposome-Mediated Delivery.
• Based on Therapeutic Area, market is studied across Allergy, Autoimmune Disorders, Cancer, and Infectious Diseases.
• Based on Route of Administration, market is studied across Intradermal, Intramuscular, Intranasal, and Subcutaneous.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing need for rapid and scalable vaccine production methodologies
    • 5.1.1.2. Enhanced regulatory frameworks supporting the approval and commercialization of DNA vaccines
    • 5.1.1.3. Increasing collaboration between public and private sectors for vaccine development
    • 5.1.1.4. Expansion of vaccination programs in developing regions boosting market growth
  • 5.1.2. Restraints
    • 5.1.2.1. Low awareness and acceptance of DNA vaccine technology among healthcare professionals and patients
    • 5.1.2.2. Technical challenges in ensuring the stability and delivery of DNA vaccines in target cells
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising prevalence of infectious diseases necessitating the development of targeted DNA vaccines
    • 5.1.3.2. Development of personalized DNA vaccines offering tailor-made solutions for individual patient needs
    • 5.1.3.3. Advancements in delivery technologies enhancing the effectiveness and acceptance of DNA vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities in ensuring cold chain logistics for the distribution of DNA vaccines across different regions
    • 5.1.4.2. Barriers to market entry for new players due to high research and development costs in the DNA vaccine industry
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. DNA Vaccine Market, by Type

• 6.1. Introduction
• 6.2. Plasmid DNA Vaccine
• 6.3. Recombinant Protein Vaccine
• 6.4. Viral Vector Vaccine

7. DNA Vaccine Market, by Application

• 7.1. Introduction
• 7.2. Allergy
• 7.3. Infectious Diseases
• 7.4. Oncology

8. DNA Vaccine Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Contract Research Organizations
• 8.4. Pharmaceutical Companies

9. DNA Vaccine Market, by Delivery Method

• 9.1. Introduction
• 9.2. Gene Gun
• 9.3. Jet Injector
• 9.4. Needle-Free Injection
  • 9.4.1. Biojector
  • 9.4.2. Electroporation

10. DNA Vaccine Market, by Technology

• 10.1. Introduction
• 10.2. Electroporation Delivery
• 10.3. Gene Gun Delivery
• 10.4. Liposome-Mediated Delivery

11. DNA Vaccine Market, by Therapeutic Area

• 11.1. Introduction
• 11.2. Allergy
• 11.3. Autoimmune Disorders
• 11.4. Cancer
• 11.5. Infectious Diseases

12. DNA Vaccine Market, by Route of Administration

• 12.1. Introduction
• 12.2. Intradermal
• 12.3. Intramuscular
• 12.4. Intranasal
• 12.5. Subcutaneous

13. Americas DNA Vaccine Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific DNA Vaccine Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa DNA Vaccine Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
• 16.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Astellas Pharma Inc.
• 3. AstraZeneca plc
• 4. Bioject Medical Technologies Inc.
• 5. Emergent BioSolutions
• 6. ExcellGene SA
• 7. Genentech, Inc.
• 8. GeneOne Life Science, Inc.
• 9. GeoVax Labs, Inc.
• 10. Immunomic Therapeutics, Inc.
• 11. Inovio Pharmaceuticals, Inc.
• 12. Johnson & Johnson
• 13. Merck & Co., Inc.
• 14. Novartis AG
• 15. OncoSec Medical Incorporated
• 16. Profectus BioSciences, Inc.
• 17. TechnoVax Inc.
• 18. Vaccibody AS
• 19. Vaxess Technologies Inc.
• 20. Vical Incorporated